Roth Affirms Curis (CRIS) at 'Buy' Following Q3 Report, Update; Pipeline Progress is Encouraging
Tweet Send to a Friend
Roth Capital reaffirms its Buy rating and $10 price target on Curis (Nasdaq: CRIS) following Q3 results reported earlier Monday.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
